Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Deffered Revenue (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $3.5 million as the latest value for Q4 2023.

  • Quarterly Non-Current Deffered Revenue changed N/A to $3.5 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2023, changed N/A year-over-year, with the annual reading at $3.5 million for FY2023, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q4 2023 was $3.5 million at Cartesian Therapeutics, down from $4.0 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $51.5 million in Q3 2020, with the low at $3.5 million in Q4 2023.
  • Average Non-Current Deffered Revenue over 5 years is $16.3 million, with a median of $14.7 million recorded in 2020.
  • The sharpest move saw Non-Current Deffered Revenue soared 22259.7% in 2019, then plummeted 72.9% in 2022.
  • Over 5 years, Non-Current Deffered Revenue stood at $14.7 million in 2019, then skyrocketed by 163.94% to $38.7 million in 2020, then plummeted by 70.53% to $11.4 million in 2021, then tumbled by 52.39% to $5.4 million in 2022, then plummeted by 34.92% to $3.5 million in 2023.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $3.5 million, $4.0 million, and $4.9 million for Q4 2023, Q3 2023, and Q2 2023 respectively.